These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

173 related articles for article (PubMed ID: 6220191)

  • 1. Biochemical markers of bone turnover in Paget's disease.
    Russell RG; Beard DJ; Cameron EC; Douglas DL; Forrest AR; Guilland-Cumming D; Paterson AD; Poser J; Preston CJ; Milford-Ward A; Woodhead S; Kanis JA
    Metab Bone Dis Relat Res; 1981; 3(4-5):255-62. PubMed ID: 6220191
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The clinical and metabolic effects of porcine calcitonin on Paget's disease of bone.
    Shai F; Baker RK; Wallach S
    J Clin Invest; 1971 Sep; 50(9):1927-40. PubMed ID: 4935444
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Biological exploration of Paget's disease].
    Eisinger J; Laponche AM; Roux H; Recordier AM
    Rev Rhum Mal Osteoartic; 1976 Feb; 43(2):105-11. PubMed ID: 131366
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Relationship between biochemical markers of bone turnover and bone scintigraphic indices in assessment of Paget's disease activity.
    Alvarez L; Peris P; Pons F; Guañabens N; Herranz R; Monegal A; Bedini JL; Deulofeu R; Martínez de Osaba MJ; Muñoz-Gómez J; Ballesta AM
    Arthritis Rheum; 1997 Mar; 40(3):461-8. PubMed ID: 9082934
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Control of osteitis deformans using glucagon, calcitonin, and mithramycin.
    Condon JR; Surtees J; Robinson V
    Postgrad Med J; 1981 Feb; 57(664):84-8. PubMed ID: 6455656
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Variable efficacy of bone remodeling biochemical markers in the management of patients with Paget's disease of bone treated with tiludronate.
    de la Piedra C; Rapado A; Díaz Diego EM; Díaz Martín MA; Aguirre C; López Gavilanes E; Díaz Curiel M
    Calcif Tissue Int; 1996 Aug; 59(2):95-9. PubMed ID: 8687976
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pamidronate sodium and calcitonin-resistant Paget's disease. Immediate response in a patient.
    Drake S; Massie JD; Postlethwaite AE; Palmieri GM
    Arch Intern Med; 1989 Feb; 149(2):401-3. PubMed ID: 2783843
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Long-term follow-up observations on treatment in Paget's disease of bone.
    Kanis JA; Gray RE
    Clin Orthop Relat Res; 1987 Apr; (217):99-125. PubMed ID: 2951050
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Metabolic consequences of bone turnover in Paget's disease of bone.
    Krane SM; Simon LS
    Clin Orthop Relat Res; 1987 Apr; (217):26-36. PubMed ID: 3549093
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Metabolic balance studies in patients with Paget's disease receiving salmon calcitonin over long periods.
    Oreopoulos DG; Husdan H; Harrison J; Meema HE; McNeill KG; Murray TM; Ogilvie R; Rapoport A
    Can Med Assoc J; 1977 Apr; 116(8):851-5. PubMed ID: 856428
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effects of two different bisphosphonates on Paget's disease of bone: ICTP assessed.
    Filipponi P; Pedetti M; Beghe F; Giovagnini B; Miam M; Cristallini S
    Bone; 1994; 15(3):261-7. PubMed ID: 8068446
    [TBL] [Abstract][Full Text] [Related]  

  • 12. An evaluation of serum osteocalcin in Paget's disease of bone and its response to diphosphonate treatment.
    Coulton LA; Preston CJ; Couch M; Kanis JA
    Arthritis Rheum; 1988 Sep; 31(9):1142-7. PubMed ID: 3048274
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Discriminative value of biochemical markers of bone turnover in assessing the activity of Paget's disease.
    Alvarez L; Guañabens N; Peris P; Monegal A; Bedini JL; Deulofeu R; Martinez de Osaba MJ; Muñoz-Gomez J; Rivera-Fillat F; Ballesta AM
    J Bone Miner Res; 1995 Mar; 10(3):458-65. PubMed ID: 7785468
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Urinary excretion of hydroxylysine and its glycosides as an index of collagen degradation.
    Krane SM; Kantrowitz FG; Byrne M; Pinnell SR; Singer FR
    J Clin Invest; 1977 May; 59(5):819-27. PubMed ID: 404321
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Paget's disease: case report].
    Wegierska M; Ignaczak P; Zalewska J; Jeka S
    Ann Acad Med Stetin; 2011; 57(3):64-9; discussion 69. PubMed ID: 23383549
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparison of serum osteocalcin with total and bone specific alkaline phosphatase and urinary hydroxyproline:creatinine ratio in patients with Paget's disease of bone.
    Kaddam IM; Iqbal SJ; Holland S; Wong M; Manning D
    Ann Clin Biochem; 1994 Jul; 31 ( Pt 4)():327-30. PubMed ID: 7979096
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Long-term treatment of Paget's disease of bone with salmon calcitonin.
    Sturtridge WC; Harrison JE; Wilson DR
    Can Med Assoc J; 1977 Nov; 117(9):1031-4. PubMed ID: 562231
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prediction of the outcome of treatment of Paget's disease of bone with bisphosphonates from short-term changes in the rate of bone resorption.
    Papapoulos SE; Frölich M
    J Clin Endocrinol Metab; 1996 Nov; 81(11):3993-7. PubMed ID: 8923849
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Quantitative evaluation of bone scintigraphy in the assessment of Paget's disease activity.
    Pons F; Alvarez L; Peris P; Guañabens N; Vidal-Sicart S; Monegal A; Pavía J; Ballesta AM; Muños-Gómez J; Herranz R
    Nucl Med Commun; 1999 Jun; 20(6):525-8. PubMed ID: 10451864
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Serum bone GLA-protein is not a sensitive marker of bone turnover in Paget's disease of bone.
    Delmas PD; Demiaux B; Malaval L; Chapuy MC; Meunier PJ
    Calcif Tissue Int; 1986 Jan; 38(1):60-1. PubMed ID: 3079654
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.